Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05918263 · ClinicalTrials.gov registry record · NA
Exercise for Tumor Suppressive Impact in Black Men With Prostate Cancer on Active Surveillance: The REMOVE Trial
A NA study of Prostate Cancer and Prostatic Neoplasms, sponsored by Dana-Farber Cancer Institute.
- Active
- Registry status
- NA
- Development phase
- 68
- Enrollment target
- 3
- Study locations
NCT05918263: Active NA study of Prostate Cancer and Prostatic Neoplasms, sponsored by Dana-Farber Cancer Institute.
NCT05918263 is a NA study of Prostate Cancer and Prostatic Neoplasms that is active but no longer recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 68 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (89% lower). The trial reports 3 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05918263, a NA study of Prostate Cancer and Prostatic Neoplasms, is active but no longer recruiting, sponsored by Dana-Farber Cancer Institute.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 68 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to determine whether a 16-week, home-based, virtually supervised exercise program will slow cancer progression of prostate cancer among Black men with prostate cancer undergoing active surveillance. The name of the study intervention involved in this study is: Aerobic high-intensity interval training (HIIT) (training exercise intervention)
Primary Outcome
The primary outcome is the between-group difference in prostate-specific antigen (PSA) levels post-intervention. Analysis of covariance will be used to detect the difference adjusting for baseline values of the outcome and other covariates.
Conditions Studied
Interventions
- BEHAVIORAL High-Intensity Interval Training Exercise Program
Study Locations (3)
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
- Brigham and Women's Hospital - Boston
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2024-01-01 |
| Est. Completion | 2027-03-31 |
| Phase | NA |
What the registry record for NCT05918263 still lists
NCT05918263 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 68 participants, a relatively small participant target, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (89% lower).
The record links to 2 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which High-Intensity Interval Training Exercise Program is the first listed.
NCT05918263 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05918263 about?
NCT05918263 is a clinical study titled "Exercise for Tumor Suppressive Impact in Black Men With Prostate Cancer on Active Surveillance: The REMOVE Trial". The purpose of this study is to determine whether a 16-week, home-based, virtually supervised exercise program will slow cancer progression of prostate cancer among Black men with prostate cancer undergoing active surveillance. The name of the study intervention involved in this study is: Aerobic ...
What is the current status of trial NCT05918263?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 68 participants. The study started on 2024-01-01. Estimated completion is 2027-03-31.
What conditions does trial NCT05918263 study?
This clinical trial studies the following conditions: Prostate Cancer, Prostatic Neoplasms.
What interventions are being tested in trial NCT05918263?
The interventions under investigation include: High-Intensity Interval Training Exercise Program (BEHAVIORAL).
Who is sponsoring clinical trial NCT05918263?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05918263 being conducted?
This trial has 3 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05918263's enrollment target sits among peer trials
68 404th of 735 higher than 329 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Improving Health Literacy in African-American Prostate Cancer Patients
RECRUITING · NA
-
Pilot Study to Investigate Magnetic Resonance (MR) Image Guided Focal Therapy in Prostate Cancer
RECRUITING · NA
-
Diffusion Basis Spectrum Imaging of the Prostate
RECRUITING · NA
-
Micro-UltraSound In Cancer - Active Surveillance
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
-
SBRT Boost for Unfavorable Prostate Cancer'
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02044497 · 68 participants · Phase 4
Population Pharmacokinetics and Pharmacogenomics of Oral Oxycodone in Pediatric Surgical Patients
- NCT03779854 · 68 participants · Phase 2
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant
- NCT04115514 · 68 participants · Phase 2
Treatment of ARDS With Instilled T3
- NCT04776395 · 68 participants · Phase 2
Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI